Friday 6 November 2026
Export GKOS’s income statement to Excel — free account
Glaukos Corporation
GKOS Healthcare Medical Devices
Glaukos Corporation’s revenue for fiscal 2025 (year ended December 2025) was $507.4 million, up 32.3% from fiscal 2024.
- Revenue
- +58.0%
- EPS
- +110.7%
- Free cash flow
- +411.2%
- Total debt
- −2.25%
Quarter to September 2026, against a year earlier
224.21
4.23
+1.92%
Follow GKOS
Alert me
| Sep '26 | Jun '26 | Mar '26 | Dec '25 | Older periods | |
|---|---|---|---|---|---|
Piotroski F-Score |
5 | 4 | 3 | 3 |
+8 more TTM periods Free account |
| (22.84%) | (25.98%) | (26.39%) | (26.38%) | ||
| (17.16%) | (19.72%) | (20.36%) | (20.09%) | ||
ROIC |
(24.60%) | (26.07%) | (26.89%) | (28.00%) | |
Return on Tangible Assets |
(30.05%) | (35.78%) | (37.21%) | (38.54%) | |
Average Days of Receivables |
79.31 | 82.73 | 79.24 | 78.12 | |
Free Cash Flow per Share |
0.61 | (0.21) | (0.60) | (0.68) | |
Free Cash Flow |
36.02 | (12.20) | (35.09) | (39.06) | |
Capital Expenditures |
(11.69) | (11.25) | (26.29) | (24.27) | |
| Other line items | |||||
Cash ROIC |
3.21% | (1.18%) | (3.46%) | (3.89%) | |
Accounts Receivable Turnover |
5.55 | 5.52 | 5.77 | 5.99 | |
Accounts Payable Turnover |
5.88 | 7.80 | 6.91 | 5.94 | |
Inventory Turnover |
2.09 | 2.07 | 1.98 | 1.84 | |
Average Days of Payables |
68.37 | 54.59 | 57.85 | 80.38 | |
Days of Inventory on Hand |
170.98 | 169.17 | 188.44 | 207.50 | |
Tax Rate |
(0.03) | (0.02) | (0.03) | (0.03) | |
Research and Development Expense of Revenue |
27.33% | 29.15% | 29.46% | 29.68% | |
Selling, General and Administrative Expense of Revenue |
62.96% | 63.10% | 64.21% | 65.38% | |
Share Based Compensation of Revenue |
12.04% | 13.09% | 12.58% | 12.46% | |
Interest Coverage |
(36.57) | (39.42) | (43.24) | (43.06) | |
Operating CF/Net income |
(0.28) | 0.01 | 0.05 | 0.08 | |
Depreciation/Fixed assets |
0.40 | 0.40 | 0.39 | 0.35 | |
Capex/Depreciation |
(0.26) | (0.25) | (0.60) | (0.62) | |
Revenue per Share |
11.68 | 10.42 | 9.50 | 8.87 | |
Operating CF per Share |
0.81 | (0.02) | (0.15) | (0.26) | |
Capex per Share |
(0.20) | (0.19) | (0.45) | (0.42) | |
Capex to Sales |
0.02 | 0.02 | 0.05 | 0.05 |
Columns are period end dates · fundamentals updated 5 Nov 2026